Technology area: Biotechnology & Pharmaceuticals
65 pending office actions • 40 art units • 60 examiners • 0 of 65 (0%) have an AI response strategy ready • 36 patents granted in the last 365 days
Boehringer Ingelheim International GmbH has 64 pending office actions in Biotechnology & Pharmaceuticals. The docket reaches 60 examiners across 38 art units, reflecting broad distribution across biotechnology examination settings.
HAVLIN, ROBERT H is the busiest examiner, with 2 pending matters. The low concentration supports a portfolio process centered on technology and art-unit organization, with examiner-specific preparation for individual responses.
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (5%) |
| §103 only | 11 (17%) |
| §102 only | 1 (2%) |
| §112 only | 12 (18%) |
| Double-patenting only | 3 (5%) |
| Double-patenting + other | 12 (18%) |
| Multi-statute (no §101) | 22 (34%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAVLIN, ROBERT H | 2 | 51.3% | +28.3% |
| BARSKY, JARED | 2 | 50.3% | +22.8% |
| CRAIGO, BAHAR ALAWI | 2 | 47.3% | +27.2% |
| MIDDLETON, DANAYA L | 2 | 49.5% | +48.8% |
| SHIAO, YIH-HORNG | 2 | 72.6% | +75.9% |
| DEBERRY, REGINA M | 1 | 50.2% | +30.8% |
| GREENE, IVAN A | 1 | 18.8% | +6.1% |
| SAEED, KAMAL A | 1 | 83.8% | +9.8% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18872318 | HSD17B13 INHIBITORS | SAEED, KAMAL A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18353133 | ANTI-IL-36R ANTIBODY FORMULATIONS | MCCOLLUM, ANDREA K | 44d overdue |
| 18544532 | SOLID DISPERSION OF A HER2 INHIBITOR | HIRT, ERIN E | 26d |
| 18039433 | ADMINISTRATION DEVICE FOR IN PARTICULAR INTRAVITREAL ADMINISTRATION OF A FLUID | BRANDT, DAVID NELSON | 30d |
| 18989164 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | GREENE, IVAN A | — |
| 18947116 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | KIM, SEONG JONG | — |
| 18848533 | NEW GLUTAMINE SYNTHETASE VARIANTS AS SELECTION MARKER | NOAKES, SUZANNE MARIE | — |
| 18808311 | BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES | GAO, ASHLEY HARTMAN | — |
| 18801886 | Cardiosafe Antidiabetic Therapy | BAEK, BONG-SOOK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18362034 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BARSKY, JARED | 26d overdue |
| 19542772 | ANTI-INTERLEUKIN-11 ANTIBODIES AND METHODS OF USE THEREOF | DEBERRY, REGINA M | — |
| 18951962 | GPR88-RECEPTOR-AGONIST | WHITE, DAWANNA SHAR-DAY | — |
| 18589552 | New therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases | HAVLIN, ROBERT H | — |
| 18585280 | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | HAVLIN, ROBERT H | — |
| 18493126 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | BARSKY, JARED | — |
| 18461850 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | CRAIGO, BAHAR ALAWI | — |
| 18327255 | HUMAN ANTIBODIES TO TN ANTIGEN | MIDDLETON, DANAYA L | — |
| Art Unit | Apps |
|---|---|
| 1626 | 4 |
| 1699 | 4 |
| 1675 | 4 |
| 1647 | 3 |
| 1621 | 3 |
| 1611 | 3 |
| 1619 | 2 |
| 1627 | 2 |
| 1628 | 2 |
| 1674 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19542772 | ANTI-INTERLEUKIN-11 ANTIBODIES AND METHODS OF USE THEREOF | DEBERRY, REGINA M | 1647 | §112 | Non-Final OA | — | Pending | Feb 18, 2026 |
| 18989164 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | GREENE, IVAN A | 1619 | §102§103§112Other | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18872318 | HSD17B13 INHIBITORS | SAEED, KAMAL A | 1626 | §112 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18951962 | GPR88-RECEPTOR-AGONIST | WHITE, DAWANNA SHAR-DAY | 1627 | §112 | Non-Final OA | — | Pending | Nov 19, 2024 |
| 18947116 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | KIM, SEONG JONG | 1621 | §102§103DP | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18848533 | NEW GLUTAMINE SYNTHETASE VARIANTS AS SELECTION MARKER | NOAKES, SUZANNE MARIE | 1656 | §102§112 | Non-Final OA | — | Pending | Sep 19, 2024 |
| 18808311 | BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES | GAO, ASHLEY HARTMAN | 1678 | §103§112 | Non-Final OA | — | Pending | Aug 19, 2024 |
| 18801886 | Cardiosafe Antidiabetic Therapy | BAEK, BONG-SOOK | 1611 | §102§103Other | Final Rejection | — | Pending | Aug 13, 2024 |
| 18800173 | CARDIO- AND RENOSAFE ANTIDIABETIC THERAPY | KOSTURKO, GEORGE W | 1621 | §102DP | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18798981 | ANTI-IL-36R ANTIBODIES FOR THE TREATMENT OF NEUTROPHILIC DERMATOSES | BUNNER, BRIDGET E | 1647 | §103 | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18789815 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | MCKOY, QUINCY ANDRE | 1626 | DP | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18789814 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | NOTTINGHAM, KYLE GREGORY | 1621 | §112 | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18785078 | PROCESS FOR THE MANUFACTURE OF A HER2 INHIBITOR | OTTON, ALICIA L | 1699 | §112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18728837 | METHOD FOR STRUCTURE ELUCIDATION | MITCHELL, NATHAN A | 2857 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18746567 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | LOVE, TREVOR M | 1611 | §103 | Final Rejection | 28d overdue | Pending | Jun 18, 2024 |
| 18706144 | HETEROCYCLIC COMPOUNDS AS STING ANTAGONISTS | RICCI, CRAIG D | 1611 | §112 | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18700748 | TRPC6 INHIBITORY COMPOUNDS FOR TREATING SEPSIS | CHENG, KAREN | 1623 | §103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18695414 | QUANTIFICATION METHOD OF POLYSORBATE IN AQUEOUS FORMULATIONS | SODERQUIST, ARLEN | 1797 | §102§103§112 | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18691241 | MEDICAMENT FOR PREVENTING AND/OR TREATING DRY EYE | BURKETT, DANIEL JOHN | 1624 | §112DP | Final Rejection | — | Pending | Mar 12, 2024 |
| 18597314 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | BERRY, LAYLA D | 1693 | §103 | Final Rejection | 66d overdue | Pending | Mar 06, 2024 |
| 18589552 | New therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases | HAVLIN, ROBERT H | 1626 | §103§112Other | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18686991 | METHOD OF DETERMINING A FUTURE COLOR VALUE OR CORRESPONDING PROPERTY AND ARRANGEMENT THEREFOR | GUTIERREZ, GISSELLE M | 2884 | §112 | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18585280 | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | HAVLIN, ROBERT H | 1626 | §103Other | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18423352 | ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES | FONTAINHAS, AURORA M | 1675 | §102§112DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18579526 | IDENTIFICATION OF COMMON TUMOR-SPECIFIC T CELL RECEPTORS AND ANTIGENS | LANDSMAN, ROBERT S | 1647 | §103§112DP | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18391748 | CRYSTALLINE FORM OF AN MDM2-p53 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103 | Final Rejection | — | Pending | Dec 21, 2023 |
| 18389892 | GLP1/GIP/NPY2 RECEPTOR TRIPLE AGONISTS | MIKNIS, ZACHARY J | 1658 | §112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18544532 | SOLID DISPERSION OF A HER2 INHIBITOR | HIRT, ERIN E | 1616 | §103§112Other | Final Rejection | 26d | Pending | Dec 19, 2023 |
| 18542910 | PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | ONDACHI, PAULINE WANJIKU MUCH | 1627 | §103§112 | Final Rejection | — | Pending | Dec 18, 2023 |
| 18561823 | A METHOD AND SYSTEM FOR INTEGRATED AND CONTINUOUS VIRAL FILTRATION, CONCENTRATION AND BUFFER EXCHANGE | MOAZZAMI, NAGHMEH NINA | 1652 | §102§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18561842 | TITER METHOD USING UV MEASUREMENT FOR CONTINUOUS BIOLOGICAL PRODUCTION | LEE, BYUNG RO | 2858 | §101§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18493126 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | BARSKY, JARED | 1628 | DP | Final Rejection | — | Pending | Oct 24, 2023 |
| 18554231 | ANTICANCER THERAPY | JARRELL, NOBLE E | 1699 | §103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18474419 | Use of Biomarkers in the Treatment of Fibrotic Conditions with a PDE4B-inhibitor | MACFARLANE, STACEY NEE | 1675 | §101§112 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18551553 | Pharmaceutical Combinations for Treating Cancer | DRISCOLL, MAUREEN VARINA | 1644 | §112DP | Final Rejection | — | Pending | Sep 20, 2023 |
| 18461850 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | CRAIGO, BAHAR ALAWI | 1699 | DP | Final Rejection | — | Pending | Sep 06, 2023 |
| 18450487 | COMBINATION THERAPY COMPRISING LONG ACTING GLP-1/GLUCAGON AND NPY2 RECEPTOR AGONISTS | JAUHARI, SACHI | 1654 | §103Other | Final Rejection | 55d | Pending | Aug 16, 2023 |
| 18275616 | ANTI-IL1RAP ANTIBODIES | NICKOL, GARY B | 1643 | §102§112 | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18362034 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BARSKY, JARED | 1628 | Other | Final Rejection | 26d overdue | Pending | Jul 31, 2023 |
| 18353133 | ANTI-IL-36R ANTIBODY FORMULATIONS | MCCOLLUM, ANDREA K | 1674 | §103§112Other | Non-Final OA | 44d overdue | Pending | Jul 17, 2023 |
| 18259098 | VIRAL CAPSID PROTEINS WITH SPECIFICITY TO HEART TISSUE CELLS | GIBBS, TERRA C | 1635 | §103§112 | Non-Final OA | — | Pending | Jun 23, 2023 |
| 18267795 | BIFUNCTIONAL ANTI-PD1/IL-7 MOLECULES | ROONEY, NORA MAUREEN | 1641 | §102§103§112Other | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18334454 | PERFUSION MEDIUM | BARRON, SEAN C | 1653 | §103 | Final Rejection | 70d | Pending | Jun 14, 2023 |
| 18256777 | FORMULATION FOR MULTI-PURPOSE APPLICATION | LU, CHENG | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18327255 | HUMAN ANTIBODIES TO TN ANTIGEN | MIDDLETON, DANAYA L | 1618 | §112 | Final Rejection | — | Pending | Jun 01, 2023 |
| 18039433 | ADMINISTRATION DEVICE FOR IN PARTICULAR INTRAVITREAL ADMINISTRATION OF A FLUID | BRANDT, DAVID NELSON | 3783 | §102§103§112 | Final Rejection | 30d | Pending | May 30, 2023 |
| 18251562 | VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103§112DP | Non-Final OA | — | Pending | May 03, 2023 |
| 18032634 | ADMINISTRATION DEVICE FOR IN PARTICULAR INTRAVITREAL ADMINISTRATION OF A FLUID | BOSQUES, EDELMIRA | 3772 | §102 | Final Rejection | — | Pending | Apr 19, 2023 |
| 18145234 | MAMMALIAN CELLS FOR PRODUCING A SECRETED PROTEIN | ANGELL, JON E | 1637 | §112Other | Non-Final OA | — | Pending | Dec 22, 2022 |
| 17759056 | MYELOID-DERIVED GROWTH FACTOR FOR USE IN TREATING OR PREVENTING FIBROSIS, HYPERTROPHY OR HEART FAILURE | BORGEEST, CHRISTINA M | 1675 | §103Other | Non-Final OA | — | Pending | Jul 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBoehringer Ingelheim International GmbH has 65 pending office actions as of October 2026, spread across 40 art units and 60 examiners.
Robert H Havlin has the most, with 2 of Boehringer Ingelheim International GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
